Mid Cap Stocks To Watch Today – December 8th

WAVE Life Sciences, ProShares UltraPro Short QQQ, AltC Acquisition, Direxion Daily TSLA Bull 2X Shares, and Structure Therapeutics are the five Mid Cap stocks to watch today, according to MarketBeat’s stock screener tool. Mid-cap stocks are shares of publicly traded companies with medium market capitalizations—commonly in the roughly $2 billion to $10 billion range, though exact cutoffs vary by index or fund. Investors view them as a middle ground between large-cap stability and small-cap growth, offering a balance of growth potential and moderate risk. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

WAVE Life Sciences (WVE)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

AltC Acquisition (ALCC)

AltC Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was formerly known as Churchill Capital Corp VIII and changed its name to AltC Acquisition Corp.

Direxion Daily TSLA Bull 2X Shares (TSLL)

Structure Therapeutics (GPCR)

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.